STOMACH CANCER DRUGS MARKET ANALYSIS

Stomach Cancer Drugs Market, By Therapy Type (Kinase Inhibitors, Nucleoside Metabolic Inhibitors, Anthracyclines, Microtubule Inhibitors, VEGF Antibodies, HER2 Receptor Antagonists, Car T Cell Therapy), By Application (Adenocarcinomas, Gastrointestinal Stromal Tumors and Carcinoid Tumors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2026

Published In : May 2019
Code : CMI2667
Pages :178
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Stomach Cancer Drugs Market - Restraints

The major restraining factors for growth of the stomach cancer drugs market are the serious side effects caused by the drugs. These include nausea and vomiting, loss of appetite and weight loss, fatigue, diarrhoea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (Deep Vein Thrombosis), nervous system damage, and heart damage in patients undergoing treatment for stomach cancer. According to the 2017, report of the American Cancer Society (ACS) on side effects of stomach cancer, chemotherapy drugs such as doxorubicin and epirubicin can cause permanent damage to the heart if used for a long time or in high doses. As per the same source, other drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.